Vol 51, No 3 (2013)
Original paper
Submitted: 2013-02-04
Accepted: 2013-08-14
Published online: 2013-11-07
Get Citation

Immunohistochemical study on survivin in sinonasal tumors and its relationship with the immunoexpression of Ki67 and Bcl-2

Olga Stasikowska-Kanicka, Malgorzata Wagrowska-Danilewicz, Marian Danilewicz
DOI: 10.5603/FHC.2013.0032
·
Folia Histochem Cytobiol 2013;51(3):225-231.
Vol 51, No 3 (2013)
ORIGINAL PAPERS
Submitted: 2013-02-04
Accepted: 2013-08-14
Published online: 2013-11-07

Abstract

The immunoexpression of the inhibitor of apoptosis protein survivin has been shown to be a significant prognostic factor in various human cancers. Immunohistochemical method was used to examine the expression of survivin, Ki67 and Bcl-2 in 20 cases of sinonasal inverted papillomas (IPs), 12 cases of sinonasal squamous cell carcinoma (SNCs) and 19 cases of nasal chronic sinusitis as a control. Nuclear immunostaining for survivin was observed in 14 of 20 (70%) cases of sinonasal IPs and 10 of 12 (83.4%) cases of SNCs. Apart from nuclear, also weak cytoplasmic immunoexpression of survivin was detected in 2 of 20 cases (10%) of sinonasal IP and moderate intense staining in 9 of 12 cases (75%) of SNC. There was no immunostaining for survivin in 19 control cases. The immunoexpression of survivin, Ki67 and Bcl-2 was significantly higher in SNCs than in sinonasal IPs and control group. Moreover, nuclear survivin and Ki67 antigen immunoexpression were significantly higher in sinonasal IPs group as compared to control group. There were statistically significant positive correlations between nuclear (but not cytoplasmic) immunoexpression of survivin and Ki67 antigen, as well as Bcl-2 oncoprotein in both tested tumors. In conclusion, our findings suggest that survivin, Ki67 and Bcl-2 may be involved in sinonasal tumorigenesis.

Abstract

The immunoexpression of the inhibitor of apoptosis protein survivin has been shown to be a significant prognostic factor in various human cancers. Immunohistochemical method was used to examine the expression of survivin, Ki67 and Bcl-2 in 20 cases of sinonasal inverted papillomas (IPs), 12 cases of sinonasal squamous cell carcinoma (SNCs) and 19 cases of nasal chronic sinusitis as a control. Nuclear immunostaining for survivin was observed in 14 of 20 (70%) cases of sinonasal IPs and 10 of 12 (83.4%) cases of SNCs. Apart from nuclear, also weak cytoplasmic immunoexpression of survivin was detected in 2 of 20 cases (10%) of sinonasal IP and moderate intense staining in 9 of 12 cases (75%) of SNC. There was no immunostaining for survivin in 19 control cases. The immunoexpression of survivin, Ki67 and Bcl-2 was significantly higher in SNCs than in sinonasal IPs and control group. Moreover, nuclear survivin and Ki67 antigen immunoexpression were significantly higher in sinonasal IPs group as compared to control group. There were statistically significant positive correlations between nuclear (but not cytoplasmic) immunoexpression of survivin and Ki67 antigen, as well as Bcl-2 oncoprotein in both tested tumors. In conclusion, our findings suggest that survivin, Ki67 and Bcl-2 may be involved in sinonasal tumorigenesis.

Get Citation

Keywords

survivin; inverted papilloma; sinonasal cancer; Ki67; Bcl-2

About this article
Title

Immunohistochemical study on survivin in sinonasal tumors and its relationship with the immunoexpression of Ki67 and Bcl-2

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 51, No 3 (2013)

Article type

Original paper

Pages

225-231

Published online

2013-11-07

DOI

10.5603/FHC.2013.0032

Bibliographic record

Folia Histochem Cytobiol 2013;51(3):225-231.

Keywords

survivin
inverted papilloma
sinonasal cancer
Ki67
Bcl-2

Authors

Olga Stasikowska-Kanicka
Malgorzata Wagrowska-Danilewicz
Marian Danilewicz

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl